EMA grants PRIME designation to Rocket’s AAV-based gene therapy
The designation for the investigational gene therapy was granted based on positive safety and efficacy data from the Phase I study in patients with Danon Disease. A favourable
Rani Therapeutics has expanded its collaboration with Celltrion for developing RT-105, an orally administered adalimumab biosimilar.